Abstract 188P
Background
Pancreatic cancer (PC) is the most lethal cancer. Pancreatic cancer patients have multiple risk factors for sarcopenia and loss of skeletal muscle mass (LSMM), which may cause greater treatment toxicities, reduced response to cancer therapy, prolonged hospitalization, impaired quality of life, and worse prognosis. The aim of this study was to study the impact of sarcopenia on chemotherapy toxicity and survival among pancreatic cancer patients who underwent chemotherapy.
Methods
A systematic review and meta-analysis was performed according to PRISMA guidelines. A literature search was conducted by two independent reviewers on all studies that included sarcopenia in hepatocellular carcinoma patients who underwent chemotherapy using PubMed, PubMed central, and Google Scholar databases. Study included elderly population was excluded. Outcome of interest included chemotherapy toxicity and overall survival. Data synthesis and statistical analysis were carried out using Review Manager software.
Results
A total of 11 studies were eligible for meta-analysis including a total of 1274 pancreatic cancer patients. All included studies were observational studies. Meta-analysis revealed a significant association between sarcopenia and overall survival (HR 1.42; 95% CI 1.20 – 1.68; P < 0.001). Sarcopenia was also associated with incidence of chemotherapy toxicity (OR 2.54; 95% CI 1.19 – 5.43; P = 0.02), including neutropenia, anemia, and thrombocytopenia. The quality of study assessed with Newcastle Ottawa Scale (NOS) showed “good” quality in all included studies.
Conclusions
Sarcopenia can give negative impact on chemotherapy toxicities and survival outcomes for pancreatic cancer patients who underwent chemotherapy. Therefore, it is important to diagnose and treat sarcopenia to reduce the chemotherapy toxicity and mortality in pancreatic cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session